DK0918795T3 - Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati - Google Patents

Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati

Info

Publication number
DK0918795T3
DK0918795T3 DK98911778T DK98911778T DK0918795T3 DK 0918795 T3 DK0918795 T3 DK 0918795T3 DK 98911778 T DK98911778 T DK 98911778T DK 98911778 T DK98911778 T DK 98911778T DK 0918795 T3 DK0918795 T3 DK 0918795T3
Authority
DK
Denmark
Prior art keywords
arg
ile
gly
thr
val
Prior art date
Application number
DK98911778T
Other languages
Danish (da)
English (en)
Inventor
Andrew J Schneider
Jack Henkin
Noel P Bouck
David W Dawson
Original Assignee
Abbott Lab
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Univ Northwestern filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0918795T3 publication Critical patent/DK0918795T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98911778T 1997-03-17 1998-03-16 Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati DK0918795T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82066797A 1997-03-17 1997-03-17
PCT/US1998/005327 WO1998041542A1 (fr) 1997-03-17 1998-03-16 Medicament antiangiogenique destine au traitement de cancer, d'arthrite et de retinopathie

Publications (1)

Publication Number Publication Date
DK0918795T3 true DK0918795T3 (da) 2005-03-14

Family

ID=25231427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98911778T DK0918795T3 (da) 1997-03-17 1998-03-16 Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati

Country Status (9)

Country Link
EP (1) EP0918795B1 (fr)
JP (2) JP4254972B2 (fr)
AT (1) ATE280781T1 (fr)
CA (1) CA2255661C (fr)
DE (1) DE69827223T2 (fr)
DK (1) DK0918795T3 (fr)
ES (1) ES2231973T3 (fr)
PT (1) PT918795E (fr)
WO (1) WO1998041542A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
ES2307337T3 (es) * 1998-05-22 2008-11-16 Abbott Laboratories Medicamentos peptidicos anti-angiogenicos.
US6774211B1 (en) 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
DE60025648T2 (de) * 1999-11-22 2006-09-14 Abbott Laboratories, Abbott Park Peptide mit antiangiogener aktivität
US6753408B1 (en) 1999-11-22 2004-06-22 Fortuna Haviv Peptides having antiangiogenic activity
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica
US6777535B1 (en) 1999-11-22 2004-08-17 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US20030119746A1 (en) * 2001-10-31 2003-06-26 Fortuna Haviv Hepta-and octapeptides having antiangiogenic activity
CN1314705C (zh) * 2005-06-03 2007-05-09 中国药科大学 高效抑制血管生成多肽及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
WO1993016716A1 (fr) * 1992-02-24 1993-09-02 Northwestern University Procede et composition d'inhibition de l'angiogenese
JPH09505555A (ja) * 1993-08-13 1997-06-03 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＴＧＦ−βの活性を刺激および阻害する方法および組成物

Also Published As

Publication number Publication date
WO1998041542A1 (fr) 1998-09-24
JP2009001576A (ja) 2009-01-08
DE69827223T2 (de) 2006-02-02
DE69827223D1 (de) 2004-12-02
ATE280781T1 (de) 2004-11-15
EP0918795A1 (fr) 1999-06-02
EP0918795B1 (fr) 2004-10-27
ES2231973T3 (es) 2005-05-16
JP4254972B2 (ja) 2009-04-15
CA2255661A1 (fr) 1998-09-24
PT918795E (pt) 2005-02-28
CA2255661C (fr) 2004-08-10
JP2001506671A (ja) 2001-05-22

Similar Documents

Publication Publication Date Title
EP0451867B1 (fr) Antagonistes d'hormone parathyroide
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
GB9720054D0 (en) Biological products
EP0254080A3 (en) Malonic acid derivatives and methods for their synthesis
DE69942035D1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
RU94036773A (ru) Домен i ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена i
CZ20022740A3 (cs) Sloučenina, způsob přípravy sloučeniny, farmaceutický prostředek a způsob léčení rakoviny
DK0918795T3 (da) Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati
EP0597997B1 (fr) Peptides relies par des ponts lanthionine
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
DE69530404T2 (de) Analogen des keratinozytenwachstumfaktors
AU5362190A (en) Novel peptides, and antidementia agents containing the same
DE69722618D1 (en) Peptide
DE69836428D1 (de) Karzinostatische wirkstoffe
CA2181590A1 (fr) Peptomeres a immunogenicite accrue
Schmittberger et al. Synthesis of the palmitoylated and prenylated C-terminal lipopeptides of the human R-and N-Ras proteins
US6268339B1 (en) Lanthionine bridged peptides
Ding et al. Structure–activity relationships of side-chain modified didemnins
WO1997010262A1 (fr) Derives peptidiques
Boyer et al. Critical role of an amino acid residue in a T cell determinant is due to its interaction with a neighboring non‐critical residue
NZ508812A (en) Peptides for the prevention or treatment of HIV
Borsuk et al. Application of substituted 2-(trimethylsilyl) ethyl esters to suppress diketopiperazine formation
Spatola Synthesis of pseudopeptides
DE3882233T2 (de) Gefässaktive peptide.
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same